SCM
Sio Capital Management Portfolio holdings
AUM
$603M
1-Year Est. Return
51.84%
This Fund
S&P 500
1 Year Est. Return
+51.84%
AUM
$395M
AUM Growth
+$146M
(+59%)
Holding
66
Top Buys
| 1 | +$31.5M | |
| 2 | +$19M | |
| 3 | +$18.1M | |
| 4 |
Kenvue
KVUE
|
+$17.2M |
| 5 |
Henry Schein
HSIC
|
+$15.2M |
Top Sells
| 1 | +$14.5M | |
| 2 | +$12.7M | |
| 3 | +$12.5M | |
| 4 |
Annexon
ANNX
|
+$9.83M |
| 5 |
SEPN
Septerna Inc
SEPN
|
+$5.19M |
Sector Composition
| 1 | Healthcare | 83.63% |
| 2 | Industrials | 12.89% |
| 3 | Consumer Staples | 3.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Humacyte Inc Warrant
HUMAW
$18.4M
| $12.2K | ﹤0.01% |
49,998
|
|
||
|
52
Annexon
ANNX
$835M
| – | – |
-4,095,764
|
|
||
53
Globus Medical
GMED
$12.8B
| – | – |
-245,570
|
|
||
54
Alector
ALEC
$265M
| – | – |
-845,531
|
|
||
55
Artivion
AORT
$1.84B
| – | – |
-158,736
|
|
||
|
ATXS
56
DELISTED
Astria Therapeutics
ATXS
| – | – |
-318,256
|
|
||
57
Avanos Medical
AVNS
$655M
| – | – |
-288,849
|
|
||
58
Embecta
EMBC
$608M
| – | – |
-31,169
|
|
||
59
Enanta Pharmaceuticals
ENTA
$415M
| – | – |
-178,774
|
|
||
60
Idexx Laboratories
IDXX
$52.4B
| – | – |
0
|
|
||
61
INmune Bio
INMB
$34.3M
| – | – |
0
|
|
||
|
MRUS
62
DELISTED
Merus
MRUS
| – | – |
-62,719
|
|
||
63
Neurocrine Biosciences
NBIX
$13.3B
| – | – |
-100,725
|
|
||
64
Travere Therapeutics
TVTX
$2.67B
| – | – |
-122,210
|
|
||
|
ATYR
65
aTyr Pharma
ATYR
$94M
| – | – |
0
|
|
||
|
MBX
66
MBX Biosciences
MBX
$1.46B
| – | – |
-241,000
|
|